Rare Cancer News & Clinical Trials » Trial

Hepatobiliary Tumors Tissue Samples Acquisition

Posted: June 24th, 2020, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Liver Cancer; Precancerous Condition; Benign Hepatobiliary Disease; Healthy, no Evidence of Disease
Interventions: Other: Gene expression analysis; Other: Genomic analysis; Other: Protein expression analysis; Other: Proteomic profiling; Other: Polymerase chain reaction; Other: Mass spectrometry; Other: Immunohistochemistry; Other: Metabolomics profiling; Other: Methylation and epigenetic analysis; Other: Liquid biopsy analysis; Other: Laboratory biomarker analysis
Sponsors: Peking Union Medical College Hospital; OrigiMed., Inc.; GeneCast Biotechnology Co., Ltd.; YuceBio Technology Co., Ltd.
Not yet recruiting

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Posted: June 22nd, 2020, 2:00pm GMT

Conditions: Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; MSI-H Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Other Solid Tumors
Intervention: Drug: CDX-527
Sponsor: Celldex Therapeutics
Not yet recruiting

Permalink for 'Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surveillance for Early Detection of Thoracic and Intra-peritoneal Malignancies in Patients With BAP1, Li-Fraumeni and Other ...'

Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surveillance for Early Detection of Thoracic and Intra-peritoneal Malignancies in Patients With BAP1, Li-Fraumeni and Other ...

Posted: June 16th, 2020, 2:00pm GMT

Conditions: Familial Cancer; BRCA1-Associate Protein-1 (BAP1) Mutations; Tumor Predisposition Syndrome (TPDS); Mesothelioma
Intervention:
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers

Posted: June 12th, 2020, 2:00pm GMT

Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; Esophageal and GEJ Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma
Interventions: Drug: tucatinib; Drug: trastuzumab; Drug: oxaliplatin; Drug: leucovorin; Drug: fluorouracil
Sponsor: Seattle Genetics, Inc.
Not yet recruiting

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Posted: June 12th, 2020, 2:00pm GMT

Conditions: Astrocytoma; Brain Cancer; Brain Metastases; Bladder Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Pleural Mesothelioma; Prostate Cancer; Sarcoma; Tongue Cancer; Thymic Carcinoma; Urinary Tract Cancer
Intervention: Drug: QBS10072S
Sponsors: Quadriga Biosciences, Inc.; Novotech (Australia) Pty Limited
Not yet recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours

Posted: June 9th, 2020, 2:00pm GMT

Conditions: Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma
Intervention: Drug: BOLD-100 in combination with FOLFOX Chemotherapy
Sponsor: Bold Therapeutics, Inc.
Not yet recruiting

the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients

Posted: June 3rd, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Other: early palliative care
Sponsor: Central Hospital, Nancy, France
Not yet recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Posted: June 3rd, 2020, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
Interventions: Drug: Combination therapy; Drug: Mono-chemotherapy
Sponsor: Zhejiang University
Recruiting

Afatinib in Advanced NRG1-Rearranged Malignancies

Posted: June 1st, 2020, 2:00pm GMT

Condition: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Intervention: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Not yet recruiting

Irreversible Electroporation of Unresectable Liver Tumors

Posted: May 27th, 2020, 2:00pm GMT

Conditions: Liver Metastases; Hepatocellular Carcinoma; Bile Duct Cancer
Intervention: Procedure: Irreversible electroporation
Sponsor: Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Recruiting

Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors

Posted: May 25th, 2020, 2:00pm GMT

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cysts; Pancreatic Endocrine Tumors; Chronic Pancreatitis; Cholangiocarcinoma, Extrahepatic; Ampullary Adenocarcinoma; Duodenal Adenocarcinoma
Interventions: Procedure: Robotic pancreaticoduodenectomy; Procedure: Open pancreaticoduodenectomy
Sponsors: Ruijin Hospital; Intuitive Surgical
Recruiting

Permalink for 'Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma'

Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma

Posted: May 13th, 2020, 2:00pm GMT

Conditions: Portal Vein Occlusion; Cholangiocarcinoma, Perihilar; Hepatocellular Carcinoma; Liver; Hypertrophy, Acute
Interventions: Procedure: PVE with coils plus TAGM; Procedure: PVE with multiple coils
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting

Advanced Endoscopy During COVID-19

Posted: May 12th, 2020, 2:00pm GMT

Conditions: Cholangitis, Secondary Biliary; Cholangiocarcinoma; Obstructive Jaundice; Pancreas Cancer; COVID-19; SARS-CoV-2
Intervention: Other: Endoscopic management according to standard of care
Sponsors: Al-Azhar University; Helwan University; National Liver Institute, Egypt
Recruiting

Permalink for 'Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.'

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Posted: May 7th, 2020, 2:00pm GMT

Condition: Unresectable Cholangiocarcinoma
Interventions: Drug: Neoadjuvant Chemo-radiotherapy; Procedure: Liver Transplantation
Sponsor: Hospital Vall d'Hebron
Recruiting

Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Posted: April 27th, 2020, 2:00pm GMT

Condition: Gallbladder Cancer
Interventions: Combination Product: Shortened hydration time and dispensary of Akynzeo; Combination Product: Standard of care
Sponsors: Imperial College Healthcare NHS Trust; Chugai Pharma UK Limited
Recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Posted: April 24th, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma, Intrahepatic
Interventions: Drug: Lenvatinib combined with gemox; Drug: Toripalimab combined with lenvatinib
Sponsor: Shanghai Zhongshan Hospital
Recruiting

Phase II Study of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion

Posted: April 20th, 2020, 2:00pm GMT

Condition: Advanced Bile Duct Cancer
Intervention: Drug: HMPL-453
Sponsor: Hutchison Medipharma Limited
Not yet recruiting

Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

Posted: April 10th, 2020, 2:00pm GMT

Conditions: Cholangiocarcinoma; Hepatocellular Carcinoma
Intervention:
Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting

Two-in-one Covered and Uncovered Metal Stent

Posted: April 7th, 2020, 2:00pm GMT

Conditions: Extrahepatic Bile Duct Cancer; Pancreatic Cancer; Lymph Node Metastases; Gallbladder Cancer
Intervention: Device: Two-in-one stent
Sponsor: Ajou University School of Medicine
Recruiting

Adjuvant Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer

Posted: April 3rd, 2020, 2:00pm GMT

Conditions: Biliary Tract Cancer; Extrahepatic Cholangiocarcinoma; Gallbladder Cancer
Interventions: Combination Product: Chemoradiation; Other: Observation
Sponsor: Sun Yat-sen University
Recruiting

Molecular Profiling of Advanced Biliary Tract Cancers

Posted: March 24th, 2020, 2:00pm GMT

Condition: Biliary Tract Cancer
Intervention: Other: Tumour and germline molecular profiling
Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Cancer Research Society
Recruiting

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

Posted: March 20th, 2020, 2:00pm GMT

Conditions: Colon Cancer; Gastric Cancer; Pancreas Cancer; Rectal Cancer; Cholangiocarcinoma; Small Bowel Cancer; Esophageal Cancer
Intervention: Other: patient engagement platform
Sponsor: Sheba Medical Center
Recruiting

Permalink for 'Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy'

Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

Posted: March 16th, 2020, 2:00pm GMT

Conditions: Primary Sclerosing Cholangitis; Cholestasis
Interventions: Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Drug: Placebo of Bezafibrate in addition to standard UDCA therapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Posted: March 13th, 2020, 2:00pm GMT

Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Recruiting

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Posted: March 12th, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: Pembrolizumab; Drug: Olaparib
Sponsor: Georgetown University
Recruiting

Chemotherapy FOLFIRINOX in Advanced or Recurrent Cholangiocarcinoma

Posted: March 12th, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma of the Bile Duct
Intervention: Drug: FOLFIRINOX Conventional chemotherapy
Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting

Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Posted: March 11th, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: KSP/QRH dimer
Sponsor: Danielle Kim Turgeon
Not yet recruiting

Permalink for 'Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma'

Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Posted: March 10th, 2020, 2:00pm GMT

Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: SNDX-6352
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; AstraZeneca
Not yet recruiting

Clinical Effect and Safety of PDT and RFA for Unresectable EHCC

Posted: March 10th, 2020, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Procedure: Photodynamic therapy; Procedure: radiofrequency ablation
Sponsor: First People's Hospital of Hangzhou
Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Posted: March 9th, 2020, 2:00pm GMT

Condition: Hepatocellular Carcinoma
Interventions: Drug: Camrelizumab; Combination Product: US/CT-guided Percutaneous Cryoablation
Sponsor: Fudan University
Recruiting

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Posted: March 6th, 2020, 3:00pm GMT

Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab; Drug: Olaparib
Sponsor: Seoul National University Hospital
Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Posted: March 6th, 2020, 3:00pm GMT

Conditions: Bile Duct Cancer; Chemotherapy Effect
Interventions: Drug: AZD6738; Drug: Durvalumab
Sponsor: Seoul National University Hospital
Recruiting

PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery

Posted: March 4th, 2020, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Apatinib; Drug: PD-1 blocking antibody SHR-1210; Drug: Capecitabine
Sponsor: Shanghai Zhongshan Hospital
Recruiting

Permalink for 'Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma'

Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma

Posted: February 19th, 2020, 3:00pm GMT

Conditions: Bile Duct Neoplasms; Colorectal Neoplasms
Interventions: Device: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.; Drug: Hepatic artery infusion pump floxuridine and dexamethasone; Drug: Systemic chemotherapy for colorectal liver metastases; Drug: Systemic chemotherapy for intrahepatic cholangiocarcinoma
Sponsor: Michael J Cavnar, MD
Recruiting

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Posted: February 11th, 2020, 3:00pm GMT

Conditions: Hepatocellular Carcinoma Stage IIIB; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma; With Hepatocellular Carcinoma; Hepatocellular Carcinoma Stage IV
Intervention: Drug: Colchicine Tablets
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University
Recruiting

Permalink for 'Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement'

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Posted: February 5th, 2020, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: Pemigatinib
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Permalink for 'mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma'

mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Posted: February 3rd, 2020, 3:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma; Liver Cancer; Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: mFOLFIRINOX; Drug: mFOLFIRI; Drug: Floxuridine; Drug: Dexamethasone; Drug: Heparin; Device: Hepatic arterial infusion pump
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Not yet recruiting

Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy

Posted: January 31st, 2020, 3:00pm GMT

Conditions: Biliary Stricture; Jaundice, Obstructive
Interventions: Device: Biliary brushing with the RX Cytology brush, Boston Scientific; Device: Biliary brushing with the Infinity® brush, US Endoscopy
Sponsor: Société Française d'Endoscopie Digestive
Not yet recruiting

Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study

Posted: January 27th, 2020, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention:
Sponsor: Beijing Tsinghua Chang Gung Hospital
Recruiting

Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

Posted: January 27th, 2020, 3:00pm GMT

Condition: Radiotherapy
Intervention: Radiation: Adaptative MR-Guided Stereotactic Body Radiotherapy
Sponsor: Centre Georges Francois Leclerc
Recruiting

Permalink for 'A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion'

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Posted: January 23rd, 2020, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: E7090
Sponsor: Eisai Co., Ltd.
Recruiting

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Posted: January 23rd, 2020, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest; AstraZeneca
Recruiting

Permalink for 'Hepatic Arterial Infusion Chemotherapy With FOLFOX and Bevacizumab Plus Toripalimab Intravenously for Advanced Biliary Tract Cancer'

Hepatic Arterial Infusion Chemotherapy With FOLFOX and Bevacizumab Plus Toripalimab Intravenously for Advanced Biliary Tract Cancer

Posted: January 6th, 2020, 3:00pm GMT

Condition: Advanced Biliary Tract Cancer
Intervention: Other: oxaliplatin, 5-fluorouracil and bevacizumab plus Toripalimab
Sponsor: Peking University
Not yet recruiting

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Posted: December 26th, 2019, 3:00pm GMT

Condition: Advanced Hepatocellular Carcinoma (HCC)
Interventions: Drug: MGD013 monotherapy; Drug: MGD013 in combination with Brivanib Alaninate
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Posted: December 26th, 2019, 3:00pm GMT

Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Toripalimab plus Lenvatinib
Sponsors: Peking Union Medical College Hospital; Shanghai Junshi Biosciences Co., LTD
Not yet recruiting

Permalink for 'Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)'

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Posted: December 18th, 2019, 3:00pm GMT

Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Recruiting

Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors

Posted: December 9th, 2019, 3:00pm GMT

Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Intervention: Drug: ABM-1310
Sponsor: ABM Therapeutics, Inc.
Recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Posted: December 6th, 2019, 3:00pm GMT

Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Not yet recruiting

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Posted: November 4th, 2019, 3:00pm GMT

Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer
Intervention: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

Posted: September 23rd, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: Fimaporfin and Gemcitabine; Drug: Gemcitabine/Cisplatin chemotherapy
Sponsor: PCI Biotech AS
Recruiting

Permalink for 'Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma'

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Posted: September 12th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR1 Gene Alteration Positive; FGFR2 Gene Alteration Positive; FGFR3 Gene Alteration Positive; IDH1 Gene Mutation; IDH1 NP_005887.2:p.R132C; IDH1 NP_005887.2:p.R132G; IDH1 NP_005887.2:p.R132H; IDH1 NP_005887.2:p.R132L; IDH1 NP_005887.2:p.R132S; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Drug: Ivosidenib; Drug: Pemigatinib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Not yet recruiting

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Posted: September 6th, 2019, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Procedure: Extend LymphAdenectomy
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting

Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma

Posted: September 3rd, 2019, 2:00pm GMT

Conditions: Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: Trifluridine/Tipiracil
Sponsors: Sunnybrook Health Sciences Centre; Taiho Pharma Canada, Inc.
Recruiting

Participation in Surgical Cancer Care

Posted: August 20th, 2019, 2:00pm GMT

Condition: Cancer
Intervention: Other: Participation with enhanced patient perioperative information
Sponsor: Linkoeping University
Recruiting

Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma

Posted: August 16th, 2019, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting

The Master Registry of Oncology Outcomes Associated With Testing and Treatment

Posted: July 22nd, 2019, 2:00pm GMT

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Not yet recruiting

$Permalink for 'A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies'$

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Posted: June 27th, 2019, 2:00pm GMT

Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Posted: April 9th, 2019, 2:00pm GMT

Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic
Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1
Sponsor: TCR2 Therapeutics
Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Posted: March 13th, 2019, 2:00pm GMT

Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions; Renal Cell Carcinoma; Melanoma
Interventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream; Biological: Bevacizumab; Biological: Ipilimumab
Sponsor: Toray Industries, Inc
Recruiting

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Posted: February 21st, 2019, 3:00pm GMT

Conditions: Melanoma; Cervical Carcinoma; Pancreatic Carcinoma; Triple Negative Breast Cancer; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Nasopharyngeal Carcinoma; Renal Cell Carcinoma; Non-small Cell Lung Carcinoma; Small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced or Metastatic Solid Tumors; Prostate Carcinoma; MSI-H; Mismatch Repair Deficiency; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Intrahepatic Cholangiocarcinoma
Interventions: Biological: XmAb®22841; Biological: Pembrolizumab (Keytruda®)
Sponsors: Xencor, Inc.; ICON Clinical Research
Recruiting

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Posted: January 29th, 2019, 3:00pm GMT

Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting

Clinical Trial of Autologous Tcm Immunotherapy in ICC

Posted: January 29th, 2019, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Recruiting

Permalink for 'Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers'

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Posted: January 14th, 2019, 3:00pm GMT

Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Recruiting

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Posted: December 31st, 2018, 3:00pm GMT

Condition: Biliary Tract Cancer
Intervention: Drug: telotristat ethyl
Sponsor: Lexicon Pharmaceuticals
Recruiting

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Posted: December 20th, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting

Permalink for 'A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)'

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Posted: September 4th, 2018, 2:00pm GMT

Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

Posted: August 2nd, 2018, 2:00pm GMT

Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting

Prospective Surveillance for Very Early Hepatocellular Carcinoma

Posted: July 17th, 2018, 2:00pm GMT

Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Posted: May 7th, 2018, 2:00pm GMT

Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Colorectal Carcinoma; Non-small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma; Mesothelioma; Neuroendocrine Carcinoma; Cervical Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of the Anus; Castration-Resistant Prostate Carcinoma; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Basal Cell Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Thymoma; Thymic Carcinoma; Squamous Cell Carcinoma of the Penis; Vulvar Carcinoma; Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy; Malignant Adnexal Neoplasms; Non-squamous Cell Salivary Gland Carcinoma
Intervention: Biological: XmAb20717
Sponsors: Xencor, Inc.; ICON plc
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Posted: March 2nd, 2018, 3:00pm GMT

Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer; COVID
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting

Permalink for 'Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma'

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Posted: July 26th, 2017, 2:00pm GMT

Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Recruiting

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Posted: July 2nd, 2017, 2:00pm GMT

Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; Tesaro, Inc.
Recruiting

Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

Posted: April 7th, 2017, 2:00pm GMT

Condition: Cholangitis
Intervention: Procedure: Injection of 37℃ contrast agent
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Posted: March 14th, 2017, 2:00pm GMT

Conditions: Cholangiocarcinoma; Biliary Tract Cancer; Adjuvant Chemotherapy; Capecitabine; Gemcitabine; Cisplatin
Interventions: Drug: Gemcitabine plus cisplatin; Drug: Capecitabine
Sponsors: Asan Medical Center; Bundang CHA Hospital; Seoul St. Mary's Hospital; Severance Hospital
Recruiting

Permalink for 'A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Posted: March 7th, 2017, 3:00pm GMT

Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Posted: December 22nd, 2016, 3:00pm GMT

Condition: Advanced Solid Tumors
Interventions: Drug: Venetoclax; Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

Permalink for 'Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery'

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

Posted: August 29th, 2016, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer; Vascular Thrombosis
Interventions: Procedure: Computed Tomography; Procedure: Single Photon Emission Computed Tomography; Drug: Technetium Tc-99m Sulfur Colloid
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting

Permalink for 'High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery'

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Posted: May 2nd, 2016, 2:00pm GMT

Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type; Periampullary Adenocarcinoma
Interventions: Procedure: Pancreatectomy; Other: Lavage
Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Posted: February 19th, 2016, 3:00pm GMT

Condition: Localized Non-Resectable Adult Liver Carcinoma
Intervention: Other: Yttrium-90 Resin Microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting

Permalink for 'Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery'

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Posted: August 11th, 2015, 2:00pm GMT

Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Posted: March 19th, 2015, 2:00pm GMT

Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
Interventions: Drug: Pemigatinib; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab; Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Posted: May 30th, 2014, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Posted: May 1st, 2014, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting

A Study of TAS-120 in Patients With Advanced Solid Tumors

Posted: February 3rd, 2014, 3:00pm GMT

Conditions: Cholangiocarcinoma; Brain Tumor; Urothelial Cancer; Other Tumor Types With FGFR2 Gene Fusions; Activating Mutations; FGFR2 Amplification
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (84 unread)

Posted: June 24th, 2020, 2:00pm GMT

Posted: June 22nd, 2020, 2:00pm GMT

Posted: June 16th, 2020, 2:00pm GMT

Posted: June 12th, 2020, 2:00pm GMT

Posted: June 12th, 2020, 2:00pm GMT

Posted: June 9th, 2020, 2:00pm GMT

Posted: June 3rd, 2020, 2:00pm GMT

Posted: June 3rd, 2020, 2:00pm GMT

Posted: June 1st, 2020, 2:00pm GMT

Posted: May 27th, 2020, 2:00pm GMT

Posted: May 25th, 2020, 2:00pm GMT

Posted: May 13th, 2020, 2:00pm GMT

Posted: May 12th, 2020, 2:00pm GMT

Posted: May 7th, 2020, 2:00pm GMT

Posted: April 27th, 2020, 2:00pm GMT

Posted: April 24th, 2020, 2:00pm GMT

Posted: April 20th, 2020, 2:00pm GMT

Posted: April 10th, 2020, 2:00pm GMT

Posted: April 7th, 2020, 2:00pm GMT

Posted: April 3rd, 2020, 2:00pm GMT

Posted: March 24th, 2020, 2:00pm GMT

Posted: March 20th, 2020, 2:00pm GMT

Posted: March 16th, 2020, 2:00pm GMT

Posted: March 13th, 2020, 2:00pm GMT

Posted: March 12th, 2020, 2:00pm GMT

Posted: March 12th, 2020, 2:00pm GMT

Posted: March 11th, 2020, 2:00pm GMT

Posted: March 10th, 2020, 2:00pm GMT

Posted: March 10th, 2020, 2:00pm GMT

Posted: March 9th, 2020, 2:00pm GMT

Posted: March 6th, 2020, 3:00pm GMT

Posted: March 6th, 2020, 3:00pm GMT

Posted: March 4th, 2020, 3:00pm GMT

Posted: February 19th, 2020, 3:00pm GMT

Posted: February 11th, 2020, 3:00pm GMT

Posted: February 5th, 2020, 3:00pm GMT

Posted: February 3rd, 2020, 3:00pm GMT

Posted: January 31st, 2020, 3:00pm GMT

Posted: January 27th, 2020, 3:00pm GMT

Posted: January 27th, 2020, 3:00pm GMT

Posted: January 23rd, 2020, 3:00pm GMT

Posted: January 23rd, 2020, 3:00pm GMT

Posted: January 6th, 2020, 3:00pm GMT

Posted: December 26th, 2019, 3:00pm GMT

Posted: December 26th, 2019, 3:00pm GMT

Posted: December 18th, 2019, 3:00pm GMT

Posted: December 9th, 2019, 3:00pm GMT

Posted: December 6th, 2019, 3:00pm GMT

Posted: November 4th, 2019, 3:00pm GMT

Posted: September 23rd, 2019, 2:00pm GMT

Posted: September 12th, 2019, 2:00pm GMT

Posted: September 6th, 2019, 2:00pm GMT

Posted: September 3rd, 2019, 2:00pm GMT

Posted: August 20th, 2019, 2:00pm GMT

Posted: August 16th, 2019, 2:00pm GMT

Posted: July 22nd, 2019, 2:00pm GMT

Posted: June 27th, 2019, 2:00pm GMT

Posted: April 9th, 2019, 2:00pm GMT

Posted: March 13th, 2019, 2:00pm GMT

Posted: February 21st, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 29th, 2019, 3:00pm GMT

Posted: January 14th, 2019, 3:00pm GMT

Posted: December 31st, 2018, 3:00pm GMT

Posted: December 20th, 2018, 3:00pm GMT

Posted: September 4th, 2018, 2:00pm GMT

Posted: August 2nd, 2018, 2:00pm GMT

Posted: July 17th, 2018, 2:00pm GMT

Posted: May 7th, 2018, 2:00pm GMT

Posted: March 2nd, 2018, 3:00pm GMT

Posted: July 26th, 2017, 2:00pm GMT

Posted: July 2nd, 2017, 2:00pm GMT

Posted: April 7th, 2017, 2:00pm GMT